Mölndal-based Amferia, a Swedish medtech firm targeted on creating revolutionary antimicrobial healthcare options, closed a €1,2 million funding spherical spearheaded by current homeowners and some new traders, together with Chalmers Ventures.
The funding will help the development of scientific improvement inside human well being and additional the commercialization of Amferia’s pipeline constructed on its proprietary platform, designed to guard and make the most of antimicrobial peptides to fight bacterial infections.
“Bacterial infections are prone to surpass most cancers and coronary heart illness as a primary reason for human deaths sooner or later, and that is largely as a consequence of resistance to generally used antibiotics. Our hydrogel know-how allows the secure and steady use of antimicrobial peptides, permitting them to successfully goal micro organism with out harming surrounding tissue. Basically, we’re utilizing antimicrobial peptides to imitate the immune system and scale back the necessity for antibiotics,” stated Anand Rajasekharan, CEO and co-founder of Amferia.
The artwork of killing micro organism
Antimicrobial peptides are identified for his or her capacity to kill micro organism as a consequence of their constructive electrostatic cost, which attracts the negatively charged micro organism. This permits the peptides to puncture bacterial membranes and destroy the cells.
Nevertheless, their fragility in pure organic environments has been a significant problem, as enzymes within the human physique can destroy these peptides inside seconds. Amferia’s hydrogel is a versatile answer that may be tailored to purposes the place killing micro organism is essential — with the added benefit that it kills even resistant micro organism.
Amferia has already signed its first business settlement with Orkla Wound Care, a number one firm inside animal wound care, to introduce a wound dressing that additionally kills resistant micro organism.
“We imagine this funding will assist Amferia advance its hydrogel platform and produce it to the marketplace for human use. A portion of the funds can be allotted in the direction of regulatory and post-regulatory work for human use. It’s going to additionally assist Amferia type new strategic partnerships to make sure a easy market entry,” added Jonas Bergman, Funding Director at Chalmers Ventures.
